financetom
Business
financetom
/
Business
/
Beyond Meat Stock Jumps On Q2 Earnings: What You Need To Know
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Beyond Meat Stock Jumps On Q2 Earnings: What You Need To Know
Aug 7, 2024 1:57 PM

Beyond Meat Inc ( BYND ) reported financial results for the second quarter after the close on Wednesday. Here's a look at the key metrics from the quarter.

Q2 Earnings: Beyond Meat ( BYND ) reported second-quarter revenue of $93.2 million, beating the consensus estimate of $87.81 million, according to Benzinga Pro. The plant-based meat company reported a second-quarter adjusted loss of 53 cents per share, missing estimates for a loss of 51 cents per share.

Total revenues decreased 8.8% on a year-over-year basis. U.S. retail channel net revenues decreased 7.5% year-over-year and U.S. foodservice channel net revenues decreased 18.9%. International retail channel net revenues fell 12.1% year-over-year and international foodservice channel net revenues decreased 2.5%.

Beyond Meat ( BYND ) ended the quarter with $158 million in cash, cash equivalents and restricted cash. The company had total outstanding debt of $1.1 billion as of June 29.

“We are pleased to report a strong quarter of progress against our 2024 plan, a pivotal year on our path to sustainable operations and profitability,” said Ethan Brown, president and CEO of Beyond Meat ( BYND ).

See Also: Traders Resume Yen-Dollar Carry Trade As Bank of Japan Pledges No Rate Hikes During Market Volatility

Outlook: Beyond Meat ( BYND ) expects full-year 2024 revenue of $320 million to $340 million. Full-year gross margin is expected to be in the mid-teens range. For comparison, gross margin came in at 14.7% in the second quarter.

Management will hold a conference call to discuss these results at 5 p.m. ET.

BYND Price Action: Beyond Meat ( BYND ) shares were up 6.49% after hours at $5.58 at the time of publication, per Benzinga Pro.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Market Chatter: Southwest Airlines Must Face Lawsuit Over Defunct Diversity Program
Update: Market Chatter: Southwest Airlines Must Face Lawsuit Over Defunct Diversity Program
Dec 9, 2024
12:36 PM EST, 12/09/2024 (MT Newswires) -- (Updates with Southwest Airlines ( LUV ) response in the third paragraph.) Southwest Airlines ( LUV ) must face a lawsuit by a group opposing affirmative action, which claims that a now defunct program offering free flights to Hispanic students was racially discriminatory, US District Judge Sidney Fitzwater ruled Friday, Reuters reported. The...
Italy wraps up probe into two Meta execs on alleged $938 mln VAT evasion by Facebook owner
Italy wraps up probe into two Meta execs on alleged $938 mln VAT evasion by Facebook owner
Dec 9, 2024
MILAN, Dec 9 (Reuters) - Italian prosecutors have wrapped up a probe into alleged tax evasion of 887.6 million euros ($937.93 million) by Facebook parent company Meta involving two executives of its Irish unit, the Milan prosecutor's office said on Monday. Closing the investigation is the formal step before prosecutors file any requests for trial, unless the suspects have first...
Disc Medicine Presents Data Showing Potential Benefits of 3 Investigational Drugs
Disc Medicine Presents Data Showing Potential Benefits of 3 Investigational Drugs
Dec 9, 2024
12:38 PM EST, 12/09/2024 (MT Newswires) -- Disc Medicine ( IRON ) said Monday that it presented data supporting the advancement of its three investigational drugs. The company said phase 2 studies showed that its drug candidate bitopertin reduces protoporphyrin IX levels and improves symptoms in adults and adolescents with erythropoietic protoporphyria, a genetic condition that can lead to liver...
AbbVie's Parkinson's disease drug improves patient mobility in late-stage study
AbbVie's Parkinson's disease drug improves patient mobility in late-stage study
Dec 9, 2024
By Mariam Sunny Dec 9 (Reuters) - AbbVie's ( ABBV ) experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out daily tasks such as eating and walking, months after the drugmaker disclosed its success in a separate study. The late-stage study tested the safety and efficacy of flexible doses of the once-daily drug, tavapadon,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved